Number of the records: 1
natalizumab
SYS d000069442 LBL 00000nz--a2200181n--4500 005 20250606221746.8 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.813 065 $a D12.776.124.790.651.114.224.060.813 065 $a D12.776.377.715.548.114.224.200.813 066 $a 01 $c 03 150 $a natalizumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 550 $7 sllk_us_auth*d039441 $Y Integrin alpha4 $w b $a integrín alfa4 550 $7 sllk_us_auth*d007155 $Y Immunologic Factors $w P $a faktory imunologické 550 $7 sllk_us_auth*d039441 $Y Integrin alpha4 $w p $a integrín alfa4 665 $a 2016 (2002) $2 eng 680 9-
$i A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE. $2 eng 750 -2
$a Natalizumab $2 eng 980 $x M
Number of the records: 1